What's Next For Johnson & Johnson Stock?
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
This Magnificent Dividend Stock Is as Healthy as It Gets
Johnson & Johnson has been a stalwart dividend stock over the years because it has maintained a healthy financial profile, ...
BioSpace9h
J&J Scraps Pipeline Assets Including Alzheimer’s and Parkinson’s Candidates
Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.
Becker's Spine Review14h
8 medtech notes: Aurora Spine, SI-Bone and more
Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the first phase of launching its Volt Variable Angle Optimized Locking ...
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating ...
Johnson & Johnson’s Growth Potential Highlighted by Strong Q3 Earnings and Promising Pipeline
David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...
Johnson & Johnson (NYSE:JNJ) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...